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Abstract 
Recent research on porous silica materials as drug carriers for amorphous and controlled drug 
delivery has shown promising results. However, due to contradictory literature reports on toxicity 
and high costs of production, it is important to explore alternative safe and inexpensive porous 
carriers.  In this study, the potential of activated carbon (AC) as an amorphous drug carrier was 
investigated using paracetamol (PA) and ibuprofen (IBU) as model drugs. The solution 
impregnation method was used for drug loading, with loading efficiency determined by UV 
spectroscopy and drug release kinetics studied using USP II dissolution apparatus. The physical 
state of the drug in the complex was characterised using differential scanning calorimetry and X-
ray diffractions techniques, whilst sites of drug adsorption were studied using Fourier transform 
infrared spectroscopy and N2 adsorption techniques. In addition, the cytotoxicity of AC on human 
colon carcinoma (Caco-2) cells was assessed using the MTT assay. Results presented here reveal 
that, for PA/AC and IBU/AC complexes, the saturation solubility of the drug in the loading solvent 
appears to have an effect on the drug loading efficiency and the physical state of the drug loaded, 
whilst drug release kinetics were affected by the wettability of the activated carbon particles. 
Furthermore, activated carbon microparticles exhibited very low cytotoxicity on Caco-2 cells at 
the concentrations tested (10-800 µg/mL). This study, therefore, supports the potential of activated 
carbon as a carrier for amorphous drug delivery. 
Keywords: Activated carbon, Amorphous drug delivery, Paracetamol, Ibuprofen, Oral drug delivery, 
Porous carrier 
Chemical compounds studied in this article 
Paracetamol (PubChem CID: 1983); Ibuprofen (PubChem CID: 3672); Ethanol (PubChem CID: 702); 
Sodium dodecyl sulphate (PubChem CID: 3423265) 
  
  
1. Introduction 
The effectiveness of an oral dosage form depends on the bioavailability of the drug, which in turn 
depends on its solubility and dissolution rate. However, more than 90% of active pharmaceutical 
ingredients have oral bioavailability issues [1] and about 40% have solubility and dissolution 
limitations [2]. With a limited number of compounds possessing drug like properties, it is 
important to develop effective techniques to improve the solubility and dissolution behaviour of 
poorly water-soluble drugs [3].  
One of the many solubility enhancing techniques includes conversion of a crystalline drug to an 
amorphous form; the dissolution rate of amorphous forms of drugs is markedly better than the 
crystalline form, especially in drugs with high crystal energy [4,5]. The absence of molecular order 
in amorphous forms of drugs allows greater motion of molecules, resulting in higher solubility, 
which plays a crucial role in achieving optimum bioavailability. However, amorphous forms have 
poor stability and often tend to convert back to crystalline forms [6].  
Several studies have been performed to develop stabilising strategies for the amorphous form of 
drugs [7,8], with loading of drugs into porous materials showing great potential [9]; the 
interactions between the carrier and the adsorbed drug, as well as the small pore size of the carriers, 
restricts the crystallisation of the drug. Various types of porous materials have been studied as 
drug carriers for amorphous drug delivery, although there are still many limitations hindering the 
technique, such as complexity of production, low drug loading efficiency, high production costs 
and safety concerns, as highlighted in Table 1. Hence, it is important to explore porous materials 
that can address the aforementioned issues.  
This current study investigates the application of activated carbon (AC) as a drug carrier for 
amorphous drug delivery. AC is inexpensive, commercially available, non-toxic and has a high 
surface area to volume ratio, which can favour development of an effective, inexpensive and safe 
carrier for oral drug delivery. AC is produced from a variety of materials rich in carbon (e.g. coal, 
wood, peat etc.), by either steam activation or chemical activation. Activation develops porosity 
in the carbon and the pore size is affected by the process of activation [28]. AC consists of a three-
dimensional interconnected pore structure, with micropores (pore width <2 nm), mesopores (pore 
width 2-50 nm) and macropores (pore width >50 nm) [29].  
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AC is extensively used in drinking water treatment and is also clinically used as an antidote to 
remove poisonings [30±32], whilst several studies have explored its use for various clinical 
applications, as noted in Table 2.  
In this study, the solution adsorption method was used for drug loading in to AC, using 
paracetamol (PA) and ibuprofen (IBU) as model drugs with different saturation solubilities in 
ethanol, in order to determine the effect of solubility on drug loading. 
 
2. Experimental section 
2.1. Materials 
Activated carbon DARCO® G-60 was purchased from Sigma Aldrich, UK. Crystalline 
paracetamol powder was obtained from GlaxoSmithKline, UK. Crystalline ibuprofen powder was 
purchased from SLS, UK. Ethanol, dimethyl sulfoxide, sodium dodecyl sulphate, sodium 
dihydrogen phosphate and disodium hydrogen phosphate were purchased from Fisher, UK. Caco-
FHOOVZHUHSXUFKDVHGIURP$7&&'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXPIRHWDOERYLQHVHUXP
trypsin-EDTA solution, anti-P\FRWLFVROXWLRQ+DQN¶VEDODQFHGVDOWVROXWLRQ MTT dye, phosphate 
buffered saline and trypan blue were purchased from Sigma Aldrich, UK.  
2.2. Characterisation of activated carbon 
2.2.1. Particle size distribution 
Particle size analysis of activated carbon was performed using laser diffraction (HELOS, 
Sympatec GmbH, Germany). 25 mg of carrier was dispersed in 200 mL of ethanol and was 
analysed for particle size in the measuring range of 0.1 to 500 µm. 
2.2.2. Cell culture and Cytotoxicity assay 
&HOOVZHUHFXOWXUHGLQ'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP'0(0 with 4500 mg/L glucose, 
L-glutamine, sodium pyruvate, sodium bicarbonate, amino acids and vitamins) with 10% FBS in 
culture flasks and incubated at 37 °C in an atmosphere of 5% CO2, and the medium was changed 
every 2 days. Cells were sub-cultured when they reached about 60% confluency. Studies were 
performed on cells between passages 100 and 120. 
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The cell suspension was diluted to achieve a density of 104 cells/mL using DMEM. Cell 
suspension was added to 96 well plates at 100 µL per well, such that each well had a density of 
1000 cells. The cells were incubated for 24 hours. The spent medium was then removed and the 
suspensions with different concentrations of carrier (10-800 µg/mL) were added to 96-well plates 
at 100 µL per well and incubated for a further 24 hours. Caco-2 cells without carrier suspension 
were used as a control. Morphology of cells was observed under light microscope. The spent 
medium was removed after 24 hours of incubation. 100 µL of fresh medium and 20 µL of 5mg/mL 
MTT in PBS solution was added to each well and incubated for 4 hours. After 4 hours, the medium 
containing MTT was removed and replaced with 100 µL DMSO. The absorbance of the resulting 
formazan solution was determined at 492 nm on a SynergyTM HT microplate reader (Biorad, 
USA).  
2.3. Preparation of drug loaded activated carbon and determination of drug loading efficiency 
Solution adsorption is a commonly used method for drug loading in to a porous carrier, where the 
carrier is immersed in a saturated drug solution for a specific duration [39]. In this study, drug was 
dissolved in 10 mL of ethanol to obtain a saturated drug solution at 20 °C (saturation solubility of 
paracetamol and ibuprofen at 20 °C is 190.61 g/kg and 886.5 g/kg of ethanol, respectively [40,41]).  
1 g of activated carbon was added to the drug solution and the suspension was stirred at 25 °C on 
a hot plate stirrer for 24 hours. The dispersion was centrifuged at 1500 rpm and the supernatant 
was collected for further analysis. The sediment was allowed to dry in an oven at 40 °C for 24 
hours.  
Drug loading efficiency was determined by UV spectroscopy (Jenway, UK). 50 mg of drug/carrier 
complex was added to 50 mL of ethanol and was stirred for 24 hours at 25 °C. The solution was 
filtered and the concentration of the drug in the filtrate was determined.  Loading efficiency of 
activated carbon was calculated using Eq. (1) as follows: 
 
                     ሺ ?ሻൌ ௪௘௜௚௛௧௢௙௧௛௘ௗ௥௨௚௜௡௖௢௠௣௟௘௫௧௢௧௔௟௪௘௜௚௛௧௢௙௖௢௠௣௟௘௫ ൈ  ? ? ?  (1) 
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2.4. Characterisation of drug loaded activated carbon complex 
2.4.1. Powdered X-ray diffraction (XRD) analysis 
The XRD patterns of the samples were recorded on a D8 ADVANCE diffractometer (Bruker, 
USA) in the angular range of 10° to 50° șZLWKDVWHSVL]HRIXVLQJD&X±.ĮVRXUFH
operated at 30 kV and 30 mA. 
2.4.2. Differential Scanning calorimetry (DSC) 
Thermal analysis was performed using a Q100 DSC instrument (TA instruments Ltd., UK). 2 mg 
of sample was weighed and transferred to a Tzero aluminium pan, with the subsequent temperature 
scan performed at a heating rate of 10 oC/min under N2 gas. Percentage crystallinity in the drug 
loaded carrier was calculated from the melting enthalpy of physical mixture of drug and carrier 
using Eq. (2) [42] : 
                                                            
௑௖ሺ ? ሻ௑௖ ?ሺ ?ሻ ൌ  ?ு௠ ?ு௠ ?     (2) 
Where ܺܿሺ ? ሻ= percentage of crystallinity in the drug/carrier complex. ܺܿ ?ሺ ?ሻ = percentage of 
crystallinity in drug/carrier physical mixture and is considered to be 100. ?ܪ݉ = melting enthalpy 
of the drug/carrier complex.  ?ܪ݉ ? = melting enthalpy of drug/carrier physical mixture. 
2.4.3. Fourier transform infra-red spectroscopy (FTIR) 
Spectra were recorded in the range of 500-4000 cm-1 using a Nicolet iS5 spectrometer 
(ThermoFisher Scientific Inc, UK) equipped with iD5 ATR (Attenuated total reflectance) 
accessory with a laminated diamond crystal at an angle of incidence of 42°. The spectra were 
obtained at a spatial resolution of 4 cm-1 and were an average of 16 scans. 
2.4.4. Nitrogen sorption analysis 
Nitrogen adsorption isotherms at 77 K were obtained using an ASAP 2420 (Accelerated surface 
area and porosimetry system, Micrometrics, USA). Activated carbon powder was degassed at 200 
°C for 4 hours and drug containing activated carbon was degassed at 40 °C for 24 hours. The 
specific surface area of the sample was computed using the Brunauer±Emmett±Teller (BET) 
method in the relative pressure range between 0.01 and 0.9. The pore size distribution of the 
sample was calculated using nonlinear density functional theory (NLDFT) method, assuming slit 
shaped pores. 
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2.4.5. Drug release studies 
Drug release from the complex was studied with a USP Type II dissolution apparatus (Erweka 
GmbH, Germany) using pure crystalline drug (equivalent to the amount of drug in the complex) 
as a control. Sodium phosphate buffer at either pH 5.8 or pH 7.2, with and without 1% w/v sodium 
dodecyl sulfate (SDS), were used as dissolution media for paracetamol and ibuprofen, 
respectively. Dissolution was performed at 37 °C with paddle stirring speed of 100 rpm. Samples 
were withdrawn at specific time intervals and replaced with fresh dissolution medium. The 
samples were filtered using 0.45 µm syringe filters and analysed using UV spectrophotometry at 
wavelengths of 257 nm and 264 nm for paracetamol and ibuprofen, respectively. 
2.5. Statistical analysis 
Statistical analysis was carried out on the data by one way ANOVA, using Graph pad prism 
software (Version 6.0 for Windows). Statistically significant differences were denoted for p values 
of less than 0.05. 
 
3. Results and Discussion 
3.1.  Characterisation of activated carbon 
Particle size of the porous carrier is an important characteristic, since, amongst other aspects, it 
may affect the drug release rate; drug loaded in deeper pores of larger particles will need to travel 
a longer distance before release [43]. Also, particle size can affect the cytotoxicity, where 
nanoparticles could result in increased toxicity compared to microparticles due to a higher chance 
of internalisation by cells [23]. However, internalisation of microparticles (0.1-10 µm) by 
endocytosis has also been observed [44,45]. Due to the above reasons, determining the particle 
size and toxicity of activated carbon is crucial. 
AC used in this study has a particle size in the range of 0.55- 87.5µm (Fig.1), with nearly 40% of 
WKHSDUWLFOHVPLQVL]H LQGLFDWLQJ WKHSRVVLELOLW\RI LQWHUQDOLVDWLRQE\FHOOVDQG WR[LFLW\
Hence, cell cytotoxicity of activated carbon on Caco-2 cells was evaluated by MTT assay. 
Although no significant toxicity was observed for concentrations 10-200 µg/mL, significant 
WR[LFLW\ ZDV REVHUYHG IRU WKH FRQFHQWUDWLRQV   JP/ S   RQH ZD\ $129$ DQG
'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVWDVVKRZQLQ)LJ7Ke slight toxicity at high concentrations 
was probably due to adsorption of nutrients in the culture medium by activated carbon particles 
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[46,47]. Nevertheless, even at the highest concentration (800 µg/mL) tested, the cell viability was 
still over 80%, suggesting that application of AC with a particle size above 0.55 µm could be safe 
for oral drug delivery. 
3.2. Drug loading into activated carbon  
After 24 hours of drying the sediment obtained from centrifugation (Section 2.3), the 
unloaded/free drug was found to crystallise as a top layer due to the evaporation of the solvent, as 
shown in Fig.3. The top crystalline layer was removed and analysed for drug content, whilst the 
bottom layer was, sieved (mesh 150-opening size 104 µm) to remove any aggregates, labelled as 
drug/carrier complex and analysed for drug loading efficiency (Table 3). During the process of 
removal of the top crystalline layer, an amount of drug loaded activated carbon was also removed; 
therefore, the total amount of activated carbon present in the drug/carrier complex is not equal to 
1000 mg. 
The higher loading efficiency for ibuprofen (IBU) compared to paracetamol (PA) could be 
attributed to the higher solubility of IBU in ethanol. Although the loading efficiency was higher, 
the fraction of adsorbed to the unadsorbed drug was lower for IBU compared to that of PA, which 
could be due to stronger interactions between IBU and ethanol or due to saturation of AC. It was 
also found that analysis of free drug in the supernatant solution can give a false estimation of drug 
loading capacity, since it does not consider the top crystalline layer of the sediment. 
3.3. Solid state analysis of drug 
DSC and XRD techniques were used to detect crystallinity in the drug/carrier complex. DSC can 
also identify any re-crystallisation of the drug that is initially present in an amorphous state. DSC 
curves for pure drug, activated carbon, drug/carrier complex and drug/carrier physical mixture are 
shown in Fig.4 (a) and (b), whilst melting temperature and melting enthalpy obtained are presented 
in Table 4; the presence of crystalline drug in the drug/carrier complex can be detected from the 
melting peak of crystalline drug. Pure paracetamol and physical mixture exhibited a melting peak 
at 169 °C, characteristic of monoclinic Form I paracetamol [48]. Pure ibuprofen and physical 
mixture exhibited a melting peak at 74.8 °C [49,50], again indicative of crystalline drug. For the 
drug/carrier complexes, no crystalline drug could be detected in PA/AC complex, whereas 
crystallinity was detected in IBU/AC complex, possibly as a consequence of the higher drug 
loading compared to PA/AC complex. Further analysis revealed that the percentage crystallinity 
in the IBU/AC complex, which was calculated from the melting enthalpy of physical mixture 
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containing an equal amount of drug as the complex, was found to be about 19% of the total drug 
present in the IBU/AC complex. These results suggest that using a saturated drug solution for 
loading is not suitable for all drugs, especially for drugs with high solubility in the respective 
solvent, and could result in increased crystallinity and reduced uniformity in the drug/carrier 
complex. Hence, it is important to determine the optimum concentration required in the loading 
solution for each drug to obtain drug/carrier complexes with no drug crystallinity. Also, it was 
observed that the melting enthalpy of the drug in the physical mixture was lower than that of the 
pure drug, which could be attributed to the interactions between AC surface and the drug 
undergoing the melting process, leading to reduced intermolecular forces in the drug [51,52]. 
Reduction of enthalpy could also be due to adsorption of drug in to the pores of AC during the 
process of melting, although the reasons behind this would require further investigation. 
The DSC results were also supported by X-ray diffraction studies (Fig.5). XRD patterns of pure 
IBU and IBU/AC physical mixture samples (Fig.5 (a)) showed characteristic peaks at 11.8°, 16.4°, 
DQGșVXJJHVWLQJWKHKLJKO\FU\VWDOOLQHQDWXUHRI,%8[53,54]. IBU/AC complex 
also showed a diffraction pattern corresponding to crystalline IBU; however, the peaks at 20° and 
22° were less intense, suggesting reduced crystallinity of IBU. XRD patterns (Fig. 5 (b)) of PA 
and PA/AC physical mixture samples showed characteristic peaks corresponding to crystalline PA 
at 15.4°, 18.1°, 20.3°, 23.3°, 24.2° and 26.4° [55]. No XRD pattern corresponding to crystalline 
PA could be detected in the case of PA/AC complex, supporting the DSC results, suggesting that 
the PA is completely present in an amorphous form, which indicates that PA is effectively loaded 
in to the pores of AC. However, with IBU/AC complex, crystallinity (19%) was detected, which 
indicates that IBU is not completely loaded in to the pores of AC and could be present as separate 
crystals. From the UV analysis, loading efficiency for IBU was found to be 44.4 %, whilst from 
DSC, 19% of the drug loaded was found to be crystalline, which is equivalent to 122 mg of IBU 
(total amount of drug in the complex was 643 mg, as shown in Table 3). Therefore, in order to 
determine the theoretical loading efficiency of IBU into the pores of AC in amorphous state, the 
amount of crystalline IBU is subtracted from the total IBU loaded, which was determined to be 
39%, suggesting that IBU/AC complex with loading higher than this could result in crystallisation 
of IBU. As such, IBU/AC complex with completely amorphous drug may be achieved by reducing 
the concentration of IBU in the loading solution, thereby avoiding overloading, although this 
would require further investigation.  
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3.4. Sites of drug adsorption 
Drug deposited on the external surface of AC can pose a risk of re-crystallisation during storage; 
as such, FTIR was used to detect any unloaded drug particles or drug deposited on the surface of 
AC. FTIR spectra of pure drug, drug/carrier physical mixture, and carrier and drug/carrier complex 
are shown in Fig. 6 (a) and (b). The sloping of spectra in samples containing AC is due to an 
increase in the absorption by carbon at lower wavenumbers, since the depth of penetration 
increases at lower wavenumbers [56]. Spectra of paracetamol and physical mixture showed peaks 
corresponding to an NH amide band stretch at 3320 cm-1 and a broad phenolic OH stretch at 3129 
cm-1. No significant peaks corresponding to PA were found in the case of PA/AC complex (Fig. 
6 (a)). Since the depth of penetration of IR in to the samples is only about 0.2-5 microns, drug 
deposited in the deeper pores may not be detected [57], which suggests that the paracetamol was 
loaded in the pores of activated carbon and was absent on external surface of the particles. 
However, with IBU/AC complex, peaks corresponding to carbonyl CO stretch at 1694 cm-1 can 
be detected, similar to the pure IBU and physical mixture (Fig. 6 (b)), which could be due to the 
presence of IBU as separate drug crystals or drug adsorbed on the external surface. Results from 
FTIR studies support the DSC and XRD data, that the drug in PA/AC complex is completely 
present in the pores of AC in a stable amorphous state. However, in the case of IBU/AC complex, 
drug is present outside the pores, either deposited on the external surface of AC or as separate 
crystals. 
3.5. In vitro drug release studies 
In vitro drug release from the complex was studied using the paddle type dissolution apparatus. 
Drug release profiles for pure drug and drug/carrier complex are shown in Fig. 7 (a) and (b). 
Unfavourably, only 54 ± 2.8% (PA/AC) and 61 ± 3% (IBU/AC) of the total drug loaded was 
released from the drug/carrier complex in sodium phosphate buffer within 10 mins, after which 
no further drug release was observed. Incomplete drug release from the complex could be due to 
poor wettability of carbon particles (powder samples floating on the surface of the dissolution 
medium could be observed). Hence, 1% SDS was added to the dissolution medium to prevent 
floating of powders; in the presence of SDS, complete drug release was achieved within 10 min 
for both drug loaded complexes. Indeed, the release rate was higher for PA/AC complex compared 
to the pure drug, whereas no marked difference was observed for IBU/AC complex, which could 
be due to the faster release of pure IBU. Both drug loaded complexes in SDS showed complete 
drug release within 10 minutes irrespective of their individual release rates (Pure PA and Pure 
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IBU in the presence of SDS achieved complete release within 20 min and 15 min, respectively), 
which could be due to the stronger influence of the porosity of the AC on the dissolution profiles 
compared to the drug characteristics, although this would require further investigation to elucidate 
the mechanisms involved. Compared to the pure crystalline drug, a higher initial release or a burst 
effect (with and without SDS) and faster complete release (with SDS) were observed for both drug 
loaded complexes, which could be due to release of drug from superficial pores and the amorphous 
nature of the drug, respectively. Compared to pure drug, amorphous drug present in the pores of 
AC has a higher surface area in contact with the dissolution media, which can result in faster 
release; thus, the drug loaded in to AC, compared to the pure crystalline drug, favoured faster 
release. 
3.6. Porosity analysis of carrier before and after drug loading 
Adsorption isotherms and pore size distribution curves are shown in Fig. 8 (a & b), with the data 
from N2 sorption studies summarised in Table 5. The adsorption/desorption isotherm of AC 
exhibited a typical type IV isotherm, with a hysteresis loop characteristic of microporous materials 
with significant mesoporosity [58]. Unloaded activated carbon particles showed higher surface 
area and pore volume compared to drug/carrier complex, demonstrating the pore filling by drug 
molecules in both PA and IBU loaded AC samples. Although the amount of drug loaded in PA/AC 
complex was markedly lower (Table 3), total pore volume was only slightly higher compared to 
IBU/AC complex, which could indicate the presence of surface adsorbed or separate, non-
associated crystals of IBU. The pore size distribution of pure AC shows the presence of pores in 
the range of 2-14 nm. Post loading, a reduction in pore size was observed for PA/AC complex, 
but the general characteristics of pure AC were retained. However, in the case of IBU/AC 
complex, pores with size > 6 nm were greatly reduced, which could be due to the reduction of 
pore size from higher drug loading.  
 
4. Conclusion and perspective   
Paracetamol and ibuprofen were successfully loaded in to activated carbon, with a drug loading 
of 20.7 ± 1 % and 44.4 ± 4 % (w/w) achieved for PA and IBU, respectively. PA loaded in to 
activated carbon was completely amorphous, whereas 19% of the IBU loaded in to activated 
carbon was found to be crystalline, suggesting that the true loading efficiency for amorphous IBU 
is only 39%. FTIR studies suggested the absence of surface adsorbed drug in PA/AC complex, 
whereas surface adsorbed drug or separate drug crystals were detected in IBU/AC complex. The 
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higher loading of IBU and presence of crystallinity in the IBU/AC complex could be due to higher 
concentration of IBU in loading solution, supporting the theory that the chemical nature of the 
drug has an effect on the loading efficiency, and the use of a saturated drug solution for drug 
loading cannot always be recommended. In vitro release studies suggested that drug release was 
complete within 10 min (in the presence of 1% SDS) for both PA/AC complex and IBU/AC 
complex. The release rate of drug/carrier complex was independent of the characteristic release 
rate of the pure drug. The low toxicity, high drug loading capacity and ability to stabilise 
amorphous drug supports the potential of activated carbon as an amorphous drug carrier. 
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Fig. 1. Particle size distribution of activated carbon obtained from laser diffraction. 
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Fig. 2. Cytotoxicity of activated carbon against Caco-2 cells. MTT assay was used to analyse the 
survival rate of Caco-2 cells incubated with different concentrartions of activated carbon. 
Statistically significant differences compared to control (0 µg/mL) are noted for P < 0.05 (*P  
0.05; ** P  0.01; *** P  0.001; **** P  0.0001, one way ANOVA and 'XQQHWW¶V PXOWLSOH
comparison test). 
 
 
 
Fig. 3: Photographic image of drug/carrier complex and crystallised drug obtained after drying the 
sediment obtained from centrifugation. Top white crystalline layer is separated and the bottom 
layer is considered as drug/Carrier complex for further analysis. 
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Fig. 4: DSC curves of (a) pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded 
activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated 
carbon (IBU/AC phy mix) (b) pure paracetamol (PA), pure activated carbon (AC), paracetamol 
loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix).  
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Fig. 5: XRD patterns of (a) pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded 
activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated 
carbon (IBU/AC phy mix) (b) pure paracetamol (PA), pure activated carbon (AC), paracetamol 
loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix). 
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Fig. 6: FTIR spectra of (a) pure paracetamol (PA), pure activated carbon (AC), paracetamol loaded 
activated carbon sample (PA/AC complex) and physical mixture of paracetamol and activated 
carbon (PA/AC phy mix) (b) pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded 
activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated 
carbon (IBU/AC phy mix).                             
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Fig. 7: Comparison of cumulative drug release from pure drug and drug loaded carrier samples at 
37°C using paddle type dissolution apparatus. (a) Curves PA and PA/AC complex represent pure 
paracetamol and paracetamol loaded activated carbon samples in sodium phosphate buffer (pH 
5.8). Curves PA-SDS and PA/AC complex-SDS represents pure paracetamol and paracetamol 
loaded activated carbon samples in sodium phosphate buffer (pH 5.8) containing 1% SDS. (b) 
Curves IBU and IBU/AC complex represent pure ibuprofen and ibuprofen loaded activated carbon 
samples in sodium phosphate buffer (pH 7.2). Curves IBU-SDS and  IBU/AC complex-SDS 
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represent pure ibuprofen and ibuprofen loaded activated carbon samples in sodium phosphate 
buffer (pH 7.2) containing 1% SDS. 
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Fig. 8: (a) Nitrogen adsorption/desorption isotherms at 77 K (b) Pore size distribution (2-14nm) 
calculated using NLDFT-slit shaped pore model, of pure activated carbon (AC), ibuprofen loaded 
activated carbon (IBU/AC complex) and paracetamol loaded activated carbon (PA/AC complex).  
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Tables 
 
Table 1: Porous materials studied as carriers for amorphous drug delivery 
Porous 
material 
Surface 
area 
Synthesis Advantages Limitations Reference 
Porous 
silicon 
Up to 1000 
m2/g 
 
Electrochemical 
etching 
Biodegradable 
Ease of synthesis 
Ease of fabrication  
Undergoes atmospheric oxidation  
Requires surface modification for stability 
Possible chemical interactions with drugs  
 
[10±13] 
Non ordered 
porous 
silica 
Up to 800 
m2/g 
Sol-gel process Ease of synthesis  Surface silanol groups can chemically interact with carboxyl 
groups of drugs via hydrogen bonding or esterification and can 
pose risk of irreversible drug adsorption or slower drug release, 
which can be disadvantageous if immediate release is preferred 
Siloxane bridges might undergo hydrolysis 
 
[12,14±19] 
Ordered 
mesoporous 
silica 
(OMS) 
Up to 1200 
m2/g 
Surfactant 
templating 
Uniform porosity 
Large surface area  
 
Complicated and expensive synthesis  
Variable Toxicity results 
Chemical interactions between surface silanol groups and 
drugs, as with non ordered porous silica 
Siloxane bridges might undergo hydrolysis 
[12,20±23] 
Ordered 
mesoporous 
carbon 
Up to 1400 
m2/g 
Hard templating 
method 
Uniform porosity 
Large surface area 
Chemically Inert 
Insoluble in biological 
fluids  
Synthesis involves use of OMS as template 
Poor wettability 
[24±27] 
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Table 2: Potential clinical applications of activated carbon 
Potential applications Result Reference 
 
Chemotherapy 
Drugs adsorbed on to AC nano particles were 
selectively delivered to regional lymph nodes and 
retained at the site of injection for a longer duration in 
rats and cancer patients. 
[33] 
 
Antacid 
Calcium carbonate or sodium carbonate adsorbed on the 
activated carbon was able to maintain ideal pH and 
neutralize gastric acidity without any rebound effect in 
vitro. 
[34,35] 
 
Photo thermal cancer 
therapy 
When exposed to laser radiation, PVP dispersed AC 
nano particles were able to convert light in to heat 
energy and resulted in tumour growth suppression at the 
site of injection in mice.  
[36] 
 
Lymph node staining 
AC of particle size < 200 nm injected was readily 
absorbed in to regional lymphatics and blackened 
lymph nodes.  
[37] 
 
Controlled release 
AC containing temperature responsive hydrogel was 
used to increase the drug loading capacity and 
mechanical strength of the hydrogel for controlled 
release.  
[38] 
 
 
 
 
 
Table 3: Comparison of ibuprofen and paracetamol loading in activated carbon 
Drug Initial quantity 
of drug a (mg) 
Quantity of drug  in 
complex (mg) 
% Loading 
efficiency  
Quantity of drug in (mg) 
Supernatant b Crystalline 
layer c 
PA 1500 208 ± 12.5 20.7 ± 1 985.5 ± 12 320.5 ± 6 
 
IBU 6900 643 ± 77.7 44.4 ± 4 5592.4  ± 159 662.3 ± 174 
 
a
 per 10 mL of Ethanol 
b
 obtained from centrifugation 
c  top crystalline layer of the sediment after drying. 
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Table 4: Melting Enthalpy and Melting points obtained from differential scanning calorimetry of 
pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded activated carbon sample 
(IBU/AC complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy mix), 
pure paracetamol (PA), paracetamol loaded activated carbon sample (PA/AC complex) and 
physical mixture of paracetamol and activated carbon (PA/AC phy mix). 
Sample Drug carrier 
ratio (w/w) 
Melting 
Enthalpy (J/g) 
Melting 
temperature (°C) 
% Crystallinity  
IBU 1:0 130.3 74.8 100 
IBU/AC phy mix 0.8:1 83.4 74.8 100 
 
IBU/AC complex 0.8:1 15.78 72 19 
PA 1:0 181 169.2 100 
PA/AC phy mix 0.25:1 27.1 169.2 100 
PA/AC complex 0.25:1 - - 0 
 
 
 
Table 5: Surface areas and pore volumes obtained from Nitrogen sorption of pure activated carbon 
(AC), ibuprofen loaded activated carbon (IBU/AC complex) and paracetamol loaded activated 
carbon (PA/AC complex)  
Sample Specific surface areaa 
(m2/g) 
Total pore volume b 
(cm3/g) 
Micro pore volume b 
(cm3/g) 
AC 1027.4 0.81 0.33 
PA/AC complex 127 0.31 0.016 
IBU/AC complex 101.8 0.23 0.014 
 
a
 Calculated  by BET method 
b Calculated by NLDFT method  
 
 
